↓ Skip to main content

Dove Medical Press

Article Metrics

Mesenchymal stromal cell therapy in COPD: from bench to bedside

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
7 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
75 Mendeley
Title
Mesenchymal stromal cell therapy in COPD: from bench to bedside
Published in
International Journal of Chronic Obstructive Pulmonary Disease, October 2017
DOI 10.2147/copd.s146671
Pubmed ID
Authors

Mariana Antunes, José Roberto Lapa e Silva, Patricia Rocco

Abstract

COPD is the most frequent chronic respiratory disease and a leading cause of morbidity and mortality. The major risk factor for COPD development is cigarette smoke, and the most efficient treatment for COPD is smoking cessation. However, even after smoking cessation, inflammation, apoptosis, and oxidative stress may persist and continue contributing to disease progression. Although current therapies for COPD (primarily based on anti-inflammatory agents) contribute to the reduction of airway obstruction and minimize COPD exacerbations, none can avoid disease progression or reduce mortality. Within this context, recent advances in mesenchymal stromal cell (MSC) therapy have made this approach a strong candidate for clinical use in the treatment of several pulmonary diseases. MSCs can be readily harvested from diverse tissues and expanded with high efficiency, and have strong immunosuppressive properties. Preclinical studies have demonstrated encouraging outcomes of MSCs therapy for lung disorders, including emphysema. These findings instigated research groups to assess the impact of MSCs in human COPD/emphysema, but clinical results have fallen short of expectations. However, MSCs have demonstrated a good adjuvant role in the clinical scenario. Trials that used MSCs combined with another, primary treatment (eg, endobronchial valves) found that patients derived greater benefit in pulmonary function tests and/or quality of life reports, as well as reductions in systemic markers of inflammation. The present review summarizes and describes the more recent preclinical studies that have been published about MSC therapy for COPD/emphysema and discusses what has already been applied about MSCs treatment in COPD patients in the clinical setting.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 9%
Student > Bachelor 7 9%
Researcher 7 9%
Student > Doctoral Student 4 5%
Other 4 5%
Other 9 12%
Unknown 37 49%
Readers by discipline Count As %
Medicine and Dentistry 13 17%
Biochemistry, Genetics and Molecular Biology 6 8%
Agricultural and Biological Sciences 4 5%
Nursing and Health Professions 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 8 11%
Unknown 38 51%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2018.
All research outputs
#3,191,152
of 13,177,477 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#379
of 1,602 outputs
Outputs of similar age
#88,385
of 312,302 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#13
of 54 outputs
Altmetric has tracked 13,177,477 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,602 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,302 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.